2024
Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis
Yin X, Li Y, Rönn M, Li S, Yuan Y, Gift T, Hsu K, Salomon J, Grad Y, Yaesoubi R. Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLOS Medicine 2024, 21: e1004424. PMID: 38976754, PMCID: PMC11262662, DOI: 10.1371/journal.pmed.1004424.Peer-Reviewed Original ResearchDrug susceptibility testingQuality-adjusted life yearsFirst-line therapyFirst-line antibioticsNet health benefitFirst-lineRetreatment regimensResistance prevalenceRapid drug susceptibility testingRate of treatment failureTreatment of gonorrheaIncidence of gonorrheaAssociated with gonorrheaEmpirical therapyTreatment failureEmpirical treatmentGonococcal infectionSusceptibility testingGonorrhea casesMSM populationGonorrheaCost-effectiveness analysisDiagnostic testsResistant strainsTherapyImpact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies N. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine 2024, 21: e1004401. PMID: 38701084, PMCID: PMC11101189, DOI: 10.1371/journal.pmed.1004401.Peer-Reviewed Original ResearchQuality-adjusted life yearsStandard of careDrug susceptibility testingRifampicin-resistant tuberculosisRR-TBEnd-of-treatmentLonger regimensTreatment strategiesTreatment outcomesBurden of drug-resistant TBCost-effective treatment strategyResistance to amikacinDrug-resistant TBSevere adverse eventsHistory of TBResistance to delamanidTB drug resistanceAnti-TB drugsLifetime costsAssociated treatment outcomesFQ-R.Average timeNatural history of TBFluoroquinolone resistanceFQ-R
2023
Cost-Effectiveness of CT, CTA, MRI, and Specialized MRI for Evaluation of Patients Presenting to the Emergency Department With Dizziness.
Tu L, Melnick E, Venkatesh A, Sheth K, Navaratnam D, Yaesoubi R, Forman H, Mahajan A. Cost-Effectiveness of CT, CTA, MRI, and Specialized MRI for Evaluation of Patients Presenting to the Emergency Department With Dizziness. American Journal Of Roentgenology 2023, 222: e2330060. PMID: 37937837, DOI: 10.2214/ajr.23.30060.Peer-Reviewed Original ResearchQuality-adjusted life yearsEvaluation of patientsSecondary prevention measuresEmergency departmentProbabilistic sensitivity analysesConventional MRICumulative quality-adjusted life yearsCost-effective strategyIncremental costNoncontrast CT headAcute stroke treatmentSpecialized MRISelection of patientsHigher quality-adjusted life yearsConventional brain MRIMarkov decision-analytic modelNon-contrast CTNoncontrast head CTHealthcare system perspectiveUse of MRIBase-case analysisPrevention measuresDecision analytic modelGreater quality-adjusted life yearsDeterministic sensitivity analysesLifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling study
You S, Yaesoubi R, Lee K, Li Y, Eppink S, Hsu K, Chesson H, Gift T, Berruti A, Salomon J, Rönn M. Lifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling study. The Lancet Regional Health - Americas 2023, 19: 100427. PMID: 36950038, PMCID: PMC10025423, DOI: 10.1016/j.lana.2023.100427.Peer-Reviewed Original ResearchQuality-adjusted life yearsGenital HSV-1Lifetime quality-adjusted life yearsGenital herpesHSV-2HSV-1Neonatal herpesLife yearsNatural historyLifetime numberNeonatal herpes infectionSubstantial health lossesHealth lossHSV-2 infectionLong-term health impactsHerpes simplex virus type 1Adverse health outcomesDays of lifeSimplex virus type 1Virus type 1Health impactsMollaret's meningitisSacral radiculitisSymptomatic recurrenceUrinary retention
2022
Estimation of the Lifetime Quality-Adjusted Life Years (QALYs) Lost Due to Syphilis Acquired in the United States in 2018
Lee K, You S, Li Y, Chesson H, Gift TL, Berruti AA, Hsu K, Yaesoubi R, Salomon JA, Rönn M. Estimation of the Lifetime Quality-Adjusted Life Years (QALYs) Lost Due to Syphilis Acquired in the United States in 2018. Clinical Infectious Diseases 2022, 76: e810-e819. PMID: 35684943, PMCID: PMC9907519, DOI: 10.1093/cid/ciac427.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCongenital syphilisHealth lossLife yearsNumber of QALYsTerms of QALYsLifetime numberBurden of syphilisSubstantial health lossesManagement of syphilisLifetime quality-adjusted life yearsAverage lifetime numberCost-effectiveness analysisPrimary infectionOverall burdenSyphilisNatural historyInfectionHealth impactsMSMChildrenMothersUnited StatesBurdenDecision tree model